Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: elmatador who wrote (138678)	1/27/2018 5:36:50 AM
From: TobagoJack	Read Replies (1) \| Respond to of 219612

hey, while you are spending time i got more good news for you china-price coming to solutions to meet imperatives should be exporting medical services soon ala thailand / malaysia, but of higher order complexity besides exporting energy by way of new reactors and such isn't it wonderful? for the greater good, etc etc geneticliteracyproject.org China poised to do gene therapy ‘better and cheaper’ than US China wants to go big on biotech and already is marching into experimental gene therapy. … So far, CAR-T has shown extraordinary results. More than 60 percent of children treated with Kymriah were cured, while the rate of full remission for patients treated with Yescarta was more than half. The big problem is price. Kymriah costs $475,000 for a single treatment; Yescarta goes for $373,000. Now China reckons it can do this better and cheaper. ... Already, China has one therapy commercially available in a free-trade zone for medical tourism on the resort island of Hainan. The product, made by Innovative Cellular Therapeutics Co., sells for 490,000 yuan ($76,000) per treatment. Prices for CAR-T can be expected to drop below 100,000 yuan in three years, according to local media reports. It's not hard to see the potential. For one thing, China's huge population means an abundance of patients for trials. For another, the nation is now flooded with venture-capital money to throw at well-qualified " sea turtles" -- as returning Chinese expats are known -- to build world-class medical labs at home. … Pricing aside, will Chinese patients accept the notion of genetically altered cells? They may not be fans of genetically modified food, viewing it as an unnecessary risk to health. But when taking that risk is the only way to save lives, attitudes can change quickly. Read full, original post: China's Great Leap Into Biotech